Table 1.
Baseline characteristics of trials studying ASCT-eligible patients
| First author | Year | Trial identifier | Phase | Regimen | Category | No. of patients | Median age (range, yr) | Median No. of prior therapies (range) | Stage III/IV (%) | Complete response < 12 mo (%) | Complete response ≥ 12 mo (%) | Primary refractory (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kang [19] | 2008 | NA | 2 | ICD | Chemotherapy | 15 | 56 (20–67) | 1 (1–3) | 46.7 | NA | NA | 60.0 |
| Gisselbrecht [4] | 2010 | NCT00137995 | 3 | R-ICE | Chemotherapy | 202 | 54 (19–65) | 1 | 58.9 | 44.1 | 55.4 | NA |
| Gisselbrecht [4] | 2010 | NCT00137995 | 3 | R-DHAP | Chemotherapy | 194 | 55 (19–65) | 1 | 62.4 | 44.8 | 53.1 | NA |
| Gyan [23] | 2013 | NA | 2 | R-NIMP | Chemotherapy | 50 | 61 (18–75) | 1 | 62.0 | 38.0 | 56.0 | 6.0 |
| Matasar [24] | 2013 | NCT00823719 | 2 | Ofatumumab+DHAP | Chemotherapy | 26 | 54 (20–66) | 1 | 65.4 | 84.6 | 15.4 | 50.0 |
| Matasar [24] | 2013 | NCT00823719 | 2 | Ofatumumab+ICE | Chemotherapy | 35 | 52 (27–79) | 1 | 65.7 | 71.4 | 22.9 | 45.7 |
| Wang [29] | 2013 | NCT00294632 | 2 | R+lenalidomide | Others | 45 | 66 (24–84) | 3 (1–4) | 60.0 | NA | NA | NA |
| Crump [21] | 2014 | NCT00078949 | 3 | R-GDP | Chemotherapy | 310 | 55 (19–71) | 1 | 70.0 | 41.6 | 26.1 | 30.6 |
| Crump [21] | 2014 | NCT00078949 | 3 | R-DHAP | Chemotherapy | 309 | 55 (23–74) | 1 | 68.0 | 41.4 | 26.9 | 30.4 |
| Wagner-Johnston [30] | 2015 | NA | 2 | Inotuzumab ozogamicin | Others | 63 | 60 (19–75) | 1 (1–2) | 58.7 | 84.1 | 15.9 | 57.1 |
| Fayad [20] | 2015 | NCT00529503 | 2b | Dacetuzumab+R-ICE | Chemotherapy | 75 | 59 (22–74) | 1 | 65.3 | 67.0 | 33.0 | NA |
| Fayad [20] | 2015 | NCT00529503 | 2b | R-ICE | Chemotherapy | 76 | 59 (31–74) | 1 | 71.1 | 66.0 | 34.0 | NA |
| Witzig [26] | 2017 | NCT00166439 | 2 | R-OAD | Chemotherapy | 45 | 69 (23–77) | 1 (1–2) | 53.3 | 53.3 | 46.7 | NA |
| van Imhoff [22] | 2017 | NCT01014208 | 3 | R-DHAP | Chemotherapy | 223 | 56 (18–79) | 1 | 63.7 | 9.9 | 29.6 | 60.5 |
| van Imhoff [22] | 2017 | NCT01014208 | 3 | Ofatumumab+DHAP | Chemotherapy | 222 | 57.5 (23–83) | 1 | 62.6 | 12.6 | 28.4 | 58.6 |
| Coyle [31] | 2020 | NCT02910063 | 2 | Blinatumomab | Others | 41 | 56 (19–75) | 2 | 73.2 | NA | NA | 68.3 |
| Kuhnl [25] | 2020 | NCT02060656 | 2 | R-Gemcitabine+ lenalidomide | Others | 21 | 58 (21–75) | 1 | 61.9 | 76.2 | 23.8 | 66.7 |
| Kuhnl [25] | 2020 | NCT02060656 | 2 | R-GDP | Chemotherapy | 19 | 59 (21–77) | 1 | 73.7 | 78.9 | 21.1 | 63.2 |
| Pan [27] | 2021 | NCT01458366 | 2 | Ofatumumab+BCE | Chemotherapy | 35 | 62 (41–78) | 1 (1–5) | 88.6 | NA | NA | 51.4 |
| Witzens-Harig [28] | 2021 | NCT01653067 | 2 | Temsirolimus+ R-DHAP | Chemotherapy | 53 | 63 (23–77) | 1 (1–2) | 64.2 | 67.9 | 32.1 | 49.1 |
| Locke [6] | 2022 | NCT03391466 | 3 | Axicabtagene ciloleucel | CAR T-cell therapy | 180 | 58 (21–80) | 1 | 77.2 | 26.1 | 0.0 | 73.9 |
| Locke [6] | 2022 | NCT03391466 | 3 | Chemotherapy+R | Chemotherapy | 179 | 60 (26–81) | 1 | 81.6 | 26.8 | 0.0 | 73.2 |
| Kamdar [7] | 2022 | NCT03575351 | 3 | Lisocabtagene maraleucel | CAR T-cell therapy | 92 | 60 (53–68 [IQR]) | 1 | 73.9 | 27.2 | 0.0 | 72.8 |
| Kamdar [7] | 2022 | NCT03575351 | 3 | Chemotherapy+R | Chemotherapy | 92 | 58 (42–65 [IQR]) | 1 | 68.5 | 26.1 | 0.0 | 73.9 |
| Bishop [11] | 2022 | NCT03570892 | 3 | Tisagenlecleucel | CAR T-cell therapy | 162 | 59.5 (19–79) | 1 | 66.0 | 34.0 | 0.0 | 66.0 |
| Bishop [11] | 2022 | NCT03570892 | 3 | Chemotherapy+R | Chemotherapy | 160 | 58 (19–77) | 1 | 61.3 | 33.1 | 0.0 | 66.9 |
ASCT, autologous stem cell transplantation; BCE, bendamustine, carboplatin, and etoposide; CAR, chimeric antigen receptor; DHAP, cytarabine, cisplatin, and dexamethasone; GDP, gemcitabine, dexamethasone, and cisplatin; ICD, irinotecan, cisplatin, and dexamethasone; IQR, interquartile range; NA, not available; NIMP, vinorelbine, ifosfamide, mitoxantrone, and prednisolone; OAD, oxaliplatin, cytarabine, and dexamethasone; R-ICE, rituximab-ifosfamide, carboplatin, and etoposide.